Sarah L. Sammons, MD

Articles by Sarah L. Sammons, MD

Treatment Advances in HR+/HER2- MBC

ByJoyce O'Shaughnessy, MD,Neil M. Iyengar, MD,Sarah L. Sammons, MD,Gabriel Hortobagyi, MD, MACP, FASCO

November 29th 2021

Final takeaways from a discussion on best practices treating HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors and PI3K therapies based on data presented at ESMO 2021.

Novel Agents Under Study for HR+/HER2- MBC

ByJoyce O'Shaughnessy, MD,Sarah L. Sammons, MD,Gabriel Hortobagyi, MD, MACP, FASCO

November 29th 2021

A panel of breast oncologists highlight exciting treatment strategies being explored in clinical trials to help address treatment limitations in HR+/HER2- metastatic breast cancer.

Sequencing Therapy in HR+/HER2- MBC

ByJoyce O'Shaughnessy, MD,Neil M. Iyengar, MD,Sarah L. Sammons, MD,Gabriel Hortobagyi, MD, MACP, FASCO

November 29th 2021

Variables that impact how breast oncologists should sequence therapies when managing patients with HR+/HER2- metastatic breast cancer.

Managing Patients With HR+ MBC on PI3K Therapy

ByJoyce O'Shaughnessy, MD,Gabriel Hortobagyi, MD, MACP, FASCO,Sarah L. Sammons, MD,Neil M. Iyengar, MD

November 22nd 2021

Breast oncologists share pearls regarding best practices treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitor therapy and mitigating treatment-related adverse events.

Sequencing Options Expand for Patients With HER2+ MBC and Brain Metastases

ByCarey K. Anders, MD, Duke Cancer Institute,Sarah L. Sammons, MD

June 5th 2020

Collectively, there are more options than ever in the space of HER2-positive breast cancer brain metastases, a significant advance for our hundreds and thousands of patients facing this challenging disease.